相似文献
1
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.
JAMA Psychiatry. 2022 Sep 1;79(9):932-934. doi: 10.1001/jamapsychiatry.2022.1776.
2
Medicines for Patients After an Opioid Overdose.
Ann Intern Med. 2018 Aug 7;169(3). doi: 10.7326/P18-0009. Epub 2018 Jun 19.
3
History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
Am J Public Health. 2021 Sep;111(9):1600-1603. doi: 10.2105/AJPH.2021.306395. Epub 2021 Aug 19.
4
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Drug Alcohol Depend. 2023 Jan 1;242:109703. doi: 10.1016/j.drugalcdep.2022.109703. Epub 2022 Nov 19.
5
Prevention of Opioid Overdose.
N Engl J Med. 2019 Jun 6;380(23):2246-2255. doi: 10.1056/NEJMra1807054.
6
Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis.
Drug Alcohol Depend. 2022 Sep 1;238:109565. doi: 10.1016/j.drugalcdep.2022.109565. Epub 2022 Jul 7.
7
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
J Subst Abuse Treat. 2021 Dec;131:108449. doi: 10.1016/j.jsat.2021.108449. Epub 2021 Apr 29.
8
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Addiction. 2022 Jul;117(7):1972-1981. doi: 10.1111/add.15862. Epub 2022 Mar 21.
9
Comparing methadone policy and practice in France and the US: Implications for US policy reform.
Int J Drug Policy. 2024 Jul;129:104487. doi: 10.1016/j.drugpo.2024.104487. Epub 2024 Jun 14.
10
Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Int J Drug Policy. 2024 Feb;124:104302. doi: 10.1016/j.drugpo.2023.104302. Epub 2024 Jan 5.
引用本文的文献
1
Interrogating perceived relevance and feasibility of HIV pre-exposure prophylaxis: A novel model of PrEP acceptability among cisgender women who inject drugs.
SSM Qual Res Health. 2023 Dec;4. doi: 10.1016/j.ssmqr.2023.100337. Epub 2023 Sep 14.
2
Innovations at the intersection of homelessness and substance use during the COVID-19 pandemic: a scoping review.
Harm Reduct J. 2025 Jul 29;22(1):132. doi: 10.1186/s12954-025-01235-7.
3
Methadone-involved overdose deaths in urban and rural communities before and after the public health emergency flexibilities for methadone take-home doses.
Drug Alcohol Depend Rep. 2025 Apr 24;15:100339. doi: 10.1016/j.dadr.2025.100339. eCollection 2025 Jun.
4
Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023.
HRB Open Res. 2025 Apr 7;8:32. doi: 10.12688/hrbopenres.14044.2. eCollection 2025.
5
Comparative effectiveness of methadone take-home dose initiation in British Columbia, Canada: protocol for a population-based retrospective cohort study using target trial guidelines.
BMJ Open. 2025 Mar 5;15(3):e095198. doi: 10.1136/bmjopen-2024-095198.
6
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.
Addict Sci Clin Pract. 2025 Feb 4;20(1):7. doi: 10.1186/s13722-025-00537-2.
7
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.
Subst Use Misuse. 2025;60(4):531-541. doi: 10.1080/10826084.2024.2440365. Epub 2024 Dec 31.
8
Clinician and Practice Characteristics Associated With Support of Office-based Methadone: Findings From a National Survey.
J Addict Med. 2025;19(2):150-156. doi: 10.1097/ADM.0000000000001388. Epub 2024 Oct 30.
9
Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.
JAMA. 2024 Dec 3;332(21):1822-1831. doi: 10.1001/jama.2024.16954.
10
Methadone Take-Home Policies and Associated Mortality: Permitting versus Non-Permitting States.
Subst Use. 2024 Aug 16;18:29768357241272379. doi: 10.1177/29768357241272379. eCollection 2024 Jan-Dec.
Zotero 插件